SCHEMBL550601

SCHEMBL550601

c1ccc2c(c1)N=c1cc3c(cc1-2)=Nc1ccccc1-3

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.39
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
MAPT P10636 3/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 2/20 0.33
APAF1 O14727 1/20 0.33
LMNA P02545 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
TSHR P16473 1/20 0.33
HK1 P19367 1/20 0.33
GALK1 P51570 1/20 0.33
HKDC1 Q2TB90 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RECQL P46063 2/20 0.31
HTT P42858 1/20 0.31
ACHE P22303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10689272 0.81 IDO1 (0.34) IDO1CYP1A2CYP2D6MAPTKDM4E
SCHEMBL6731218 0.81 MEN1 (0.46) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL22130438 0.81 ABCG2 (0.33)
SCHEMBL4488526 0.81
SCHEMBL3173360 0.80 IDO1 (0.31) IDO1
SCHEMBL4137855 0.78 CYP1A2 (0.31) CYP1A2CYP2D6
SCHEMBL4138703 0.78
SCHEMBL17863803 0.78 MBNL1 (0.33) IDO1ACHE
SCHEMBL16556384 0.78 ACHE (0.33) IDO1ACHE
SCHEMBL15475376 0.77 MEN1 (0.36) MEN1KMT2AALDH1A1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119431405-B Indolo [3,2-b ] carbazole dimer derivative, and preparation method and application thereof 沈阳药科大学 2026-05-15 CN claimed
CN-122054890-A Molecular assembly method of D-A type blending system and application thereof 苏州工学院 2026-05-15 CN claimed
CN-119431405-A Indolo [3,2-b ] carbazole dimer derivative, and preparation method and application thereof 沈阳药科大学 2025-02-14 CN claimed
CN-118894862-A Indolo [3,2-B ] carbazole structural derivative and electroluminescent device thereof 西安欧得光电材料有限公司 2024-11-05 CN claimed
CN-114853763-B D-pi-A compound and application thereof in passivation of perovskite solar cell 大连理工大学 2023-06-09 CN claimed
CN-114853763-A D-pi-A compound and application thereof in perovskite solar cell passivation 大连理工大学 2022-08-05 CN claimed
WO-2022094174-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ESOPHAGEAL CONDITIONS CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2022-05-05 WO claimed
US-20210060158-A1 AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2021-03-04 US claimed
EP-3684410-A1 AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY Institut Curie (FR) 2020-07-29 EP claimed
WO-2019115576-A1 METHODS OF TREATING HEART FAILURE INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2019-06-20 WO claimed
WO-2019057744-A1 AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY INSTITUT CURIE (FR) 2019-03-28 WO claimed
US-20180256617-A1 METHODS FOR EXTENDING LIFESPAN AND METHODS OF SCREENING KNOWN PHARMACOLOGICAL AGENTS FOR NEW USES LONGEVICA THERAPEUTICS INC. 2018-09-13 US claimed
US-20160343960-A1 Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2016-11-24 US claimed
WO-2016168670-A2 METHODS FOR EXTENDING LIFESPAN AND METHODS OF SCREENING KNOWN PHARMACOLOGICAL AGENTS FOR NEW USES LONGEVICA THERAPEUTICS INC. (US) 2016-10-20 WO claimed
EP-1030663-B1 TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS DESIGNED NUTRITIONAL PRODUCTS (US) 2010-03-10 EP claimed
US-6613792-B1 Treatment of premenstrual syndrome and menopause DESIGNED NUTRITIONAL PRODUCTS, INC. 2003-09-02 US claimed
EP-1030663-A4 TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS DESIGNED NUTRITIONAL PRODUCTS (US) 2002-06-26 EP claimed
WO-2001008637-A2 TREATMENT OF PREMENSTRUAL SYNDROME AND MENOPAUSE DESIGNED NUTRITIONAL PRODUCTS, INC. (US) 2001-02-08 WO claimed
EP-1030663-A1 TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS Designed Nutritional Products Inc. (US) 2000-08-30 EP claimed
WO-1999017768-A1 TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS DESIGNED NUTRITIONAL PRODUCTS, INC. (US) 1999-04-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160343960-A1 Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device CALCOCO2, CYBA, INTS9 IDO1 244/4885CYP1A2 1386/4885CYP2D6 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.